Drug intelligence / Profile preview

abatacept + certolizumab pegol + etanercept + golimumab + sarilumab + tocilizumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

This is a combination of six biologic disease-modifying antirheumatic drugs (bDMARDs) used for the treatment of rheumatoid arthritis. The combination includes a T-lymphocyte inhibitor (abatacept), TNF inhibitors (certolizumab pegol, etanercept, golimumab), and IL-6 inhibitors (sarilumab, tocilizumab). These medications are typically used in patients with moderate to severe rheumatoid arthritis who have not responded adequately to conventional DMARDs.

Targets

CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)

Beyond the preview

Go deeper on abatacept + certolizumab pegol + etanercept + golimumab + sarilumab + tocilizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abatacept + certolizumab pegol + etanercept + golimumab + sarilumab + tocilizumab.

Explore the full profile